RDIF, AstraZeneca and others invest in treatments for resistant arterial hypertension
pharmafile | February 1, 2022 | News story | Medical Communications |
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), AstraZeneca, and Unicorn Capital Partners, a biotech-specialised VC fund, announced the agreement to invest in Target Medicals.
This will enable the development of an aldosterone synthase inhibitor, a key enzyme responsible for the production of aldosterone. This hormone is an essential component of renin-angiotensin-aldosterone system, which regulates circulating blood volume and arterial blood pressure.
Globally, there are around one billion people living with arterial hypertension, of which 10% develop a resistant form of the disease. This is typically diagnosed when regular intake of three or more antihypertensive drugs, including diuretic, does not lead to the reduction of blood pressure down to 140/90 mmHg or lower.
When this disease is inadequately controlled, the risk of various health complications, including potentially fatal ones, is increased. This highlights a significant unmet need in new pharmacological options for the treatment of resistant arterial hypertension.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said: “This investment is part of RDIF’s strategy to support innovation and promote breakthrough healthcare technologies. It demonstrates the synergy between RDIF and RVC, which was achieved through the integration of a wide network of partners, the successful track record of cooperation between RDIF and leading companies in medicine and pharmaceuticals, as well as expertise of funds with participation of RVC in the Russian venture capital market.
“This investment will help Target Medicals at the testing stage of the drug as well as launching it later on the global market, which will significantly improve the quality of life for millions.”
Lina Adams
